2q61: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Binding to helix 12 of the ligand-binding domain of PPARgamma is required, for full agonist activity. Previously, the degree of stabilization of the, activation function 2 (AF-2) surface was thought to correlate with the, degree of agonism and transactivation. To examine this mechanism, we, probed structural dynamics of PPARgamma with agonists that induced graded, transcriptional responses. Here we present crystal structures and amide, H/D exchange (HDX) kinetics for six of these complexes. Amide HDX revealed, each ligand induced unique changes to the dynamics of the ligand-binding, domain (LBD). Full agonists stabilized helix 12, whereas intermediate and, partial agonists did not at all, and rather differentially stabilized, other regions of the binding pocket. The gradient of PPARgamma, transactivation cannot be accounted for solely through changes to the, dynamics of AF-2. Thus, our understanding of allosteric signaling must be, extended beyond the idea of a dynamic helix 12 acting as a molecular, switch.
Binding to helix 12 of the ligand-binding domain of PPARgamma is required for full agonist activity. Previously, the degree of stabilization of the activation function 2 (AF-2) surface was thought to correlate with the degree of agonism and transactivation. To examine this mechanism, we probed structural dynamics of PPARgamma with agonists that induced graded transcriptional responses. Here we present crystal structures and amide H/D exchange (HDX) kinetics for six of these complexes. Amide HDX revealed each ligand induced unique changes to the dynamics of the ligand-binding domain (LBD). Full agonists stabilized helix 12, whereas intermediate and partial agonists did not at all, and rather differentially stabilized other regions of the binding pocket. The gradient of PPARgamma transactivation cannot be accounted for solely through changes to the dynamics of AF-2. Thus, our understanding of allosteric signaling must be extended beyond the idea of a dynamic helix 12 acting as a molecular switch.
 
==Disease==
Known diseases associated with this structure: Abdominal body fat distribution, modifier of OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Diabetes mellitus, insulin-resistant, with acanthosis nigricans and hypertension OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Glioblastoma, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Insulin resistance, severe, digenic OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Lipodystrophy, familial partial OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Obesity, resistance to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Obesity, severe OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]]


==About this Structure==
==About this Structure==
Line 10: Line 13:


==Reference==
==Reference==
Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism., Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR, Structure. 2007 Oct;15(10):1258-71. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17937915 17937915]
Partial agonists activate PPARgamma using a helix 12 independent mechanism., Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR, Structure. 2007 Oct;15(10):1258-71. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=17937915 17937915]
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Bruning, J.B.]]
[[Category: Bruning, J B.]]
[[Category: Nettles, K.W.]]
[[Category: Nettles, K W.]]
[[Category: SF1]]
[[Category: SF1]]
[[Category: ligand binding protein]]
[[Category: ligand binding protein]]
[[Category: protein-ligand complex]]
[[Category: protein-ligand complex]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 12:44:11 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:36:21 2008''

Revision as of 19:36, 21 February 2008

File:2q61.jpg


2q61, resolution 2.197Å

Drag the structure with the mouse to rotate

Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145

OverviewOverview

Binding to helix 12 of the ligand-binding domain of PPARgamma is required for full agonist activity. Previously, the degree of stabilization of the activation function 2 (AF-2) surface was thought to correlate with the degree of agonism and transactivation. To examine this mechanism, we probed structural dynamics of PPARgamma with agonists that induced graded transcriptional responses. Here we present crystal structures and amide H/D exchange (HDX) kinetics for six of these complexes. Amide HDX revealed each ligand induced unique changes to the dynamics of the ligand-binding domain (LBD). Full agonists stabilized helix 12, whereas intermediate and partial agonists did not at all, and rather differentially stabilized other regions of the binding pocket. The gradient of PPARgamma transactivation cannot be accounted for solely through changes to the dynamics of AF-2. Thus, our understanding of allosteric signaling must be extended beyond the idea of a dynamic helix 12 acting as a molecular switch.

DiseaseDisease

Known diseases associated with this structure: Abdominal body fat distribution, modifier of OMIM:[601487], Diabetes mellitus, insulin-resistant, with acanthosis nigricans and hypertension OMIM:[601487], Glioblastoma, susceptibility to OMIM:[601487], Insulin resistance, severe, digenic OMIM:[601487], Lipodystrophy, familial partial OMIM:[601487], Obesity, resistance to OMIM:[601487], Obesity, severe OMIM:[601487]

About this StructureAbout this Structure

2Q61 is a Single protein structure of sequence from Homo sapiens with as ligand. Full crystallographic information is available from OCA.

ReferenceReference

Partial agonists activate PPARgamma using a helix 12 independent mechanism., Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR, Structure. 2007 Oct;15(10):1258-71. PMID:17937915

Page seeded by OCA on Thu Feb 21 18:36:21 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA